Nuclear Receptors in Osteoclasts

Overview

Journal Curr Opin Pharmacol

Specialty Pharmacology

Date 2020 Jun 23

PMID 32569976

Citations 4

Authors

Seyeon Bae

Steven Zeng

Kyung-Hyun Park-Min

Affiliations

Soon will be listed here.

Abstract

Osteoclasts are bone-resorbing cells that play an essential role in the remodeling of bone under physiological conditions and numerous pathological conditions, such as osteoporosis, bone metastasis, and inflammatory bone erosion. Nuclear receptors are crucial to various physiological processes, including metabolism, development and inflammation, and function as transcription factors to activate target genes. Synthetic ligands of nuclear receptors are also available for the treatment of metabolic and inflammatory diseases. However, dysregulated bone phenotypes have been documented in patients who take synthetic nuclear receptor ligands as a therapy. Therefore, the effect of nuclear receptors on bone cells has become an important area of exploration; additionally, the molecular mechanisms underlying the action of nuclear receptors in osteoclasts have not been completely understood. Here, we cover the recent progress in our understanding of the roles of nuclear receptors in osteoclasts.

Citing Articles

Osteoclast Activation and Inflammatory Bone Diseases: Focusing on Receptors in Osteoclasts.

Zhao W, Li J, Su T, Wang C, Fu Y, Li C J Inflamm Res. 2025; 18:3201-3213.

PMID: 40059949 PMC: 11890017. DOI: 10.2147/JIR.S507269.

Osteoporosis: interferon-gamma-mediated bone remodeling in osteoimmunology.

Li S, Liu G, Hu S Front Immunol. 2024; 15:1396122.

PMID: 38817601 PMC: 11137183. DOI: 10.3389/fimmu.2024.1396122.

Regulation of Osteoclast Differentiation and Activity by Lipid Metabolism.

Kim H, Oh B, Park-Min K Cells. 2021; 10(1).

PMID: 33430327 PMC: 7825801. DOI: 10.3390/cells10010089.

Editorial overview: Immunomodulation 2020 - nuclear receptors.

Roszer T Curr Opin Pharmacol. 2020; 53:vi-viii.

PMID: 33183678 PMC: 7832667. DOI: 10.1016/j.coph.2020.10.013.

The Crossroads between Infection and Bone Loss.

Carvalho Oliveira T, Gomes M, Gomes A Microorganisms. 2020; 8(11).

PMID: 33182721 PMC: 7698271. DOI: 10.3390/microorganisms8111765.

References

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

Wei W, Schwaid A, Wang X, Wang X, Chen S, Chu Q . Ligand Activation of ERRα by Cholesterol Mediates Statin and Bisphosphonate Effects. Cell Metab. 2016; 23(3):479-91. PMC: 4785078. DOI: 10.1016/j.cmet.2015.12.010. View

Wang F, Lin C, Chen Y, Wang C, Yang K, Huang Y . Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology. 2005; 146(5):2415-23. DOI: 10.1210/en.2004-1050. View

Deblois G, Giguere V . Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nat Rev Cancer. 2012; 13(1):27-36. DOI: 10.1038/nrc3396. View

Tanaka S, Nakamura K, Takahasi N, Suda T . Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005; 208:30-49. DOI: 10.1111/j.0105-2896.2005.00327.x. View

Lu N, Cidlowski J . Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell. 2005; 18(3):331-42. DOI: 10.1016/j.molcel.2005.03.025. View

Khosla S, Oursler M, Monroe D . Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23(11):576-81. PMC: 3424385. DOI: 10.1016/j.tem.2012.03.008. View

Nelson H, Humphrey L, Nygren P, Teutsch S, Allan J . Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288(7):872-81. DOI: 10.1001/jama.288.7.872. View

Delhon I, Gutzwiller S, Morvan F, Rangwala S, Wyder L, Evans G . Absence of estrogen receptor-related-alpha increases osteoblastic differentiation and cancellous bone mineral density. Endocrinology. 2009; 150(10):4463-72. DOI: 10.1210/en.2009-0121. View

10.

Robertson Remen K, Lerner U, Gustafsson J, Andersson G . Activation of the liver X receptor-β potently inhibits osteoclastogenesis from lipopolysaccharide-exposed bone marrow-derived macrophages. J Leukoc Biol. 2012; 93(1):71-82. DOI: 10.1189/jlb.0712339. View

11.

Janowski B, Willy P, Devi T, Falck J, Mangelsdorf D . An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996; 383(6602):728-31. DOI: 10.1038/383728a0. View

12.

Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein R . The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010; 24(2):323-34. PMC: 2817608. DOI: 10.1210/me.2009-0354. View

13.

Dhiman V, Bolt M, White K . Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. Nat Rev Genet. 2017; 19(3):160-174. DOI: 10.1038/nrg.2017.102. View

14.

. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999; 97(2):161-3. DOI: 10.1016/s0092-8674(00)80726-6. View

15.

Knowles H . Hypoxic regulation of osteoclast differentiation and bone resorption activity. Hypoxia (Auckl). 2016; 3:73-82. PMC: 5045091. DOI: 10.2147/HP.S95960. View

16.

Grey A . Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2007; 19(2):129-37. DOI: 10.1007/s00198-007-0477-y. View

17.

Chen H, Stuart W, Hu B, Nguyen L, Huang G, Clemens T . Creation of estrogen resistance in vivo by transgenic overexpression of the heterogeneous nuclear ribonucleoprotein-related estrogen response element binding protein. Endocrinology. 2005; 146(10):4266-73. DOI: 10.1210/en.2005-0160. View

18.

Lewis-Tuffin L, Cidlowski J . The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci. 2006; 1069:1-9. DOI: 10.1196/annals.1351.001. View

19.

Heitzer M, Wolf I, Sanchez E, Witchel S, DeFranco D . Glucocorticoid receptor physiology. Rev Endocr Metab Disord. 2007; 8(4):321-30. DOI: 10.1007/s11154-007-9059-8. View

20.

Bouvard B, Audran M, Legrand E, Chappard D . Ultrastructural characteristics of glucocorticoid-induced osteoporosis. Osteoporos Int. 2009; 20(6):1089-92. DOI: 10.1007/s00198-009-0864-7. View